On May 12th, the biaseparations.com website will be retired and migrated tosartorius.com.Learn moreabout our combined offering today!

3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit

Manufacturing of Safer AAV Vectors

Speaker: Ales Strancar, Managing Director of Sartorius BIA Separations 

Key message:

  • Recent clinical trials revealed the immune response to AAV vectors might be a bottleneck in AAV gene therapy.
  • One of the key reasons for the immune response is AAV purity. Improved manufacturing, especially purification process, is therefore mandatory for safer gene therapy.
  • In addition to hc proteins and hc DNA, removal of empty and partial AAV capsids, infectious viruses and endotoxin will be presented in this paper.

Register Now!

  • from
    20Jun2023
    until
    21Jun2023
  • 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit
  • Location: Vienna, Austria